Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test at 50 could flag your risk of five diseases. can an app stop them?

NCT ID NCT07820800

Prevention Sponsor: University of Eastern Finland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers in South Savo, Finland, invite residents turning 45, 50 or 55 to take a blood test that measures many small molecules at once. The test estimates each person's 10-year risk of type 2 diabetes, heart attack, stroke, chronic kidney disease and fatty liver disease. People at moderate or high risk are split into three groups that each get a different digital lifestyle programme for up to 12 months, and those at highest risk also see a doctor to optimise standard preventive medicines. The trial asks whether early risk information plus digital support lowers future disease risk and improves wellbeing, and whether the whole approach is worth the cost.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital lifestyle apps and coaching (BitHabit, Onnikka, Oma Eloisa) plus a blood-based NMR metabolomics risk assessment
What this could lead to
If it works, this could give health systems a cheap way to spot middle-aged people at risk of diabetes, heart, kidney and liver disease early and steer them to app-based prevention before illness takes hold.
What could go wrong
Digital apps often fail to hold people's attention, and a risk score alone does not change behaviour. The trial runs for 12 months, so any effect on actual disease diagnoses may take years to show, and results in Finland may not transfer to other health systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Permanent resident of the Eloisa Wellbeing Services County (South Savo, Finland), or has selected Eloisa primary health care as their primary public care provider * Turning 45, 50, or 55 years of age during calendar year 2026 * NMR metabolomics-based risk assessment result classified as low, moderate, or high multi-disease risk * Able to provide written informed consent digitally * Able to use a smartphone, tablet, or computer for digital application access * Resident of Finland with a Finnish personal identity code (required for health register linkage) Exclusion Criteria: * Currently pregnant or breastfeeding * Incarcerated or under forensic psychiatric care * Significantly impaired capacity for self-determination * Insufficient proficiency in Finnish to provide informed consent and complete study procedures * No Finnish personal identity code

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebrovascular disorder chronic kidney disease chronic renal failure syndrome coronary artery disorder Coronary Disease fatty liver disease metabolic dysfunction-associated steatotic liver disease myocardial infarction stroke disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular disease Chronic kidney disease Coronary heart disease Fatty liver disease Myocardial infarction Stroke Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.